ALX Oncology Holdings Inc. announced the first patient has been dosed in the ASPEN-07 study evaluating evorpacept, a next generation CD47 blocker, in combination with PADCEV® (enfortumab vedotin-ejfv), an antibody drug conjugate (ADC), in patients with urothelial cancer (UC). ASPEN-07 is a phase 1, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of evorpacept in combination with enfortumab vedotin-ejfv in subjects with unresectable locally advanced or metastatic UC (NCT05524545).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.88 USD | -10.50% | -15.15% | -60.51% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.51% | 306M | |
+16.49% | 122B | |
+21.73% | 115B | |
+21.63% | 26.64B | |
-21.81% | 19.91B | |
-16.87% | 16.32B | |
-44.74% | 15.52B | |
-18.81% | 15.49B | |
+62.72% | 14.83B | |
+3.09% | 13.67B |
- Stock Market
- Equities
- ALXO Stock
- News ALX Oncology Holdings Inc.
- ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer